Request demo

Podcast: Why AI won’t save the 90% of clinical trials that still fail

  • Podcast
SHARE

 

Insights podcast series with BioSpace

We’re delighted to be working with BioSpace as part of their Insights podcast series.

Episode 2 In this episode, Cresset CSO, Mark Mackey and VP of AI, Mutlu Dogruel join BioSpace’s Head of Insights, Lori Ellis to discuss the potential role of AI in reducing preclinical costs and the potential impact on clinical trial fail rates.

Listen to the podcast: Why AI Won’t Save the 90% of Clinical Trials That Still Fail – BioSpace

Related Science Resources

Application of generative AI to design covalent inhibitors of prolyl oligopeptidase
Generative chemistry is revolutionizing drug discovery, using AI to efficiently explore entirely new areas of chemical space in the search for...
Best practices for using the Flare™ AI Assistants
The introduction of AI assistants in Flare V11 reflects a broader objective: to streamline routine molecular modelling tasks, reduce efforts...
Prioritization of new molecule design using QSAR models – 2D- and 3D-QSAR studies
Introduction The viral main protease Mpro is a crucial enzyme for the replication of the severe acute respiratory syndrome coronavirus...

Subscribe & Don't Miss Out

Receive our newsletter to be among the first to hear about product releases, case studies, opinion articles, events and more.
Subscribe